Gossamer Bio, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Greg Ciongoli, founder and managing partner of Adiumentum Capital Management and prior partner at Baupost Group, was appointed to Gossamer Bio's Board of Directors effective September 16, 2026, and will serve on the Audit Committee. Ciongoli brings investment and value-creation experience and currently serves on boards of REGENXBIO, Zymeworks, and Atara Biotherapeutics. No financial terms, compensation details, or equity grants were disclosed in the filing.
Why this rating
Board appointment is routine corporate governance; no financial impact, equity dilution, or strategic change disclosed. Does not alter business trajectory.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.